Evolocumab

Introduction Overview

Generic Name

evolocumab

Brand Name

Repatha

Dosage Form

Prefilled single-dose SureClick autoinjector (140 mg/mL), prefilled single-dose syringe (140 mg/mL), single-dose Pushtronex system (420 mg/3.5 mL; on-body infusor with prefilled cartridge)

Drug Class

PCSK9 inhibitors

Pharmacokinetics

Absorption:
Evolocumab is administered subcutaneously, with bioavailability estimated to be approximately 72%. After subcutaneous injection, peak plasma concentrations are generally achieved within 3 to 4 days. Its absorption can be influenced by injection site, patient factors such as body weight, and presence of autoimmune conditions. Repatha’s onset of action is rapid, allowing effective LDL-C reduction within 1 week of initiation. The slow absorption profile ensures sustained plasma levels adequate for biweekly or monthly dosing.

Distribution:
Evolocumab exhibits a moderate volume of distribution consistent with monoclonal antibodies, approximately 7.6 L. It is predominantly confined to vascular and interstitial spaces given its large molecular size and hydrophilic properties. It does not readily cross cell membranes or the blood-brain barrier. Protein binding is high but reversible, and distribution is influenced by PCSK9 expression levels and receptor-mediated processes. Due to its target-mediated disposition, distribution kinetics may be nonlinear at different dosing levels.

Metabolism:
Being a monoclonal antibody, evolocumab is metabolized primarily via proteolytic catabolism ubiquitous to immunoglobulin G molecules. It is degraded into small peptides and amino acids through reticuloendothelial system pathways and cellular lysosomal degradation, without involvement of hepatic cytochrome P450 enzymes. Metabolism is not expected to be affected by hepatic impairment, and no active metabolites have been identified.

Elimination:
Evolocumab is eliminated via two pathways: target-mediated clearance through binding and internalization with PCSK9, and non-specific proteolytic degradation. Its elimination half-life ranges approximately from 11 to 17 days, supporting dosing every two weeks or monthly. Clearance can be influenced by the presence of circulating PCSK9 and antibody levels. Renal clearance is negligible due to molecular size. There is no accumulation after repeated dosing when given per recommended schedules. Clinical studies demonstrate steady-state levels are reached within 12 weeks of treatment initiation.

Dosage Forms

Available Dosage Forms:
-Repatha is available as a prefilled single-dose SureClick autoinjector containing 140 mg/mL solution.
-It is also supplied as a prefilled single-dose syringe with 140 mg/mL concentration.
-A single-dose Pushtronex system (an on-body infusor) with a prefilled cartridge delivering 420 mg/3.5 mL is available for monthly dosing.
-Both SureClick autoinjector and syringes come in latex-containing or latex-free versions; the Pushtronex system is latex-free.

Dosages for Adults and Adolescents:
-The typical adult dosage for hyperlipidemia and cardiovascular risk reduction is 140 mg subcutaneously every two weeks or 420 mg subcutaneously once a month.
-For heterozygous familial hypercholesterolemia (HeFH), the same adult dosing regimen applies.
-For homozygous familial hypercholesterolemia (HoFH), adults initiate at 420 mg once monthly; if clinical response is inadequate after 12 weeks, dosing may increase to 420 mg every two weeks.
-Adults undergoing lipid apheresis may start with 420 mg every two weeks post-apheresis session.

Specific Patient Populations:
-Children aged 10 years and older with HeFH: 140 mg subcutaneously every two weeks or 420 mg once monthly are recommended.
-Children aged 10 years and older with HoFH: initiate 420 mg once monthly, with possible increase to every two weeks based on response.
-Dosing in children under 10 years or with other types of hyperlipidemia is not established and not approved.

Clinical Guidelines:
-Doses should be administered via subcutaneous injection in the thigh, upper arm, or abdomen (avoiding two-inch area around navel).
-The Pushtronex system delivers the 420 mg dose over approximately 9 minutes and allows for moderate patient activity during administration.
-Multiple injections with separate devices may be required for 420 mg dose if not using Pushtronex.
-Patient or caregiver training is essential to ensure correct administration technique.
-Doses should not be missed; if a dose is missed, it should be given within 7 days of scheduled time to maintain efficacy.

Mechanism Of Action

Repatha (evolocumab) is a fully human monoclonal antibody targeting the protein PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9). PCSK9 is a key regulator of cholesterol metabolism that modulates the number of low-density lipoprotein receptors (LDL-R) present on hepatocyte surfaces. Under normal physiology, PCSK9 binds to LDL-Rs and promotes their lysosomal degradation, reducing receptor recycling and thereby limiting the liver’s capacity to clear LDL cholesterol from the bloodstream.

Evolocumab binds with high affinity and specificity to circulating PCSK9, preventing its interaction with LDL receptors. This blockade halts the degradation of LDL-Rs, increases recycling and number of LDL-Rs on hepatic cells, and significantly enhances hepatic uptake and clearance of LDL cholesterol from the plasma. As a result, plasma concentrations of 'bad' LDL cholesterol decline markedly, by approximately 50-60% or more in clinical settings.

At the cellular level, this mechanism efficiently restores LDL receptor availability, improving cholesterol homeostasis. The biochemical interaction specifically disrupts the PCSK9-LDL receptor binding interface without affecting other proteolytic functions of PCSK9. This highly targeted approach results in substantial lipid lowering without the broader pleiotropic effects seen with some other lipid-lowering agents.

Comparatively, while statins inhibit cholesterol synthesis and indirectly upregulate LDL-R expression, Repatha works post-translationally by stabilizing LDL receptors against degradation. This complementary mechanism allows use as monotherapy or in combination with statins or other LDL-C lowering agents, often producing additive effects. Clinical trials have robustly demonstrated that targeting PCSK9 with evolocumab not only lowers LDL-C but reduces major adverse cardiovascular events, confirming the clinical benefits of its fundamental molecular action.

Pharmacological Actions

Selective inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) binding to LDL receptors.
Increased recycling and surface expression of LDL receptors on hepatocytes.
Enhanced clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream.
Reduction of plasma LDL cholesterol levels by approximately 50-60%.
Adjunctive lipid-lowering effect when combined with statins, resulting in greater LDL-C reduction.
Improvement in cardiovascular risk profile by lowering LDL-C and reducing major adverse cardiovascular events.
Long duration of action due to monoclonal antibody pharmacokinetics, supporting biweekly or monthly dosing schedules.
Minimally metabolized by hepatic enzymes; metabolized by proteolytic pathways.
Lack of significant interaction with cytochrome P450 system, reducing drug interaction potential.
Immunomodulation primarily limited to target protein binding without systemic immunosuppression.
Reduction of atherosclerotic plaque progression secondary to LDL-C lowering.
Potential to improve endothelial function via LDL-related mechanisms.
No direct effect on high-density lipoprotein cholesterol (HDL-C) levels.
Does not affect triglycerides significantly beyond LDL-C lowering.
Demonstrated safety and tolerability in long-term use in clinical trials.

Therapeutic Or Clinical Uses

Reduction of elevated LDL cholesterol in adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH).
Lowering LDL cholesterol in children aged 10 years and older with HeFH as adjunct therapy.
Treatment of homozygous familial hypercholesterolemia (HoFH) in adults and children aged 10 years and older.
Adjunct to diet and maximally tolerated statin therapy or other LDL-lowering therapies.
Reduction of risk of major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, stroke, unstable angina requiring hospitalization, and coronary revascularization in patients with established cardiovascular disease.
Management of hypercholesterolemia in patients who are unable to achieve LDL-C targets with standard therapies.
Alternative lipid-lowering option for statin-intolerant patients when clinically appropriate.
Use in patients with atherosclerotic cardiovascular disease to reduce LDL-C levels and associated morbidity.
Support for lowering LDL-C in patients with genetic lipid disorders.
Adjunctive therapy in patients undergoing lipid apheresis.
Treatment of hyperlipidemia in patients with suboptimal response to statins or ezetimibe.
Use in high-risk populations with elevated LDL-C despite lifestyle modifications and existing pharmacotherapy.
Reduction of LDL-C as a primary preventive measure in select high-risk cardiovascular patients.
Therapeutic option approved for long-term management of cholesterol with proven cardiovascular benefits.
Potential role in comprehensive cardiovascular risk reduction strategies.

Side Or Adverse Effects

Injection site reactions including redness, pain, or bruising are common.
Upper respiratory tract infections presenting as cold symptoms like runny nose and sore throat.
Flu-like symptoms including fever, fatigue, and malaise.
Back pain reported among some patients during therapy.
Potential elevation in blood sugar levels and increased risk of new-onset diabetes.
Serious allergic reactions such as anaphylaxis, characterized by rash, itching, swelling of face, lips, tongue or throat, difficulty breathing or swallowing.
Rare hypersensitivity reactions to the monoclonal antibody or excipients including latex sensitivity.
Nasopharyngitis and other mild respiratory tract infections have been observed.
Urinary tract infections reported in some patients.
Possible headache and muscle pain though less frequent compared to statins.
Fatigue and dizziness in some patients with long-term use.
Hypersensitivity to injection components such as dry natural rubber latex present in some device needle covers.
Gastrointestinal disturbances like nausea or abdominal discomfort in rare cases.
Elevated liver enzymes are uncommon but monitored during treatment.
Potential for rare neutralizing antibody formation, though clinical impact is minimal.

Precautions

Screen patients for known hypersensitivity or allergy to evolocumab or any illicit ingredients including constituents of the injection device.
Assess for latex allergy due to presence of dry natural rubber in certain injection devices; use latex-free devices when necessary.
Monitor blood glucose levels in patients at risk for diabetes; adjust diabetes management accordingly.
Use cautiously in patients with severe renal or hepatic impairment, although metabolism is not significantly hepatic or renal.
Pregnancy safety is not established; use only if potential benefits justify risks and counsel patients regarding risks.
Breastfeeding safety unknown; consider risk-benefit and monitor infants for adverse effects.
Not recommended for use in children under 10 years due to insufficient safety and efficacy data.
Ensure proper injection technique and site rotation to minimize injection site reactions.
Advise patients not to shake the medication or use if solution discoloration or particles are present.
Avoid injecting into bruised, tender, scarred, or hardened skin.
Patient education is critical to adherence and proper administration.
Monitor for signs of hypersensitivity reactions or injection site infections.
Caution with use in patients with immunocompromised status; immunogenicity profile is low but should be observed.
Advise patients to maintain concomitant lipid-lowering therapies and lifestyle modifications.
Emphasize the importance of adherence to dosing schedules to maintain LDL-C control.

Warnings

Potential for severe allergic or anaphylactic reactions necessitates immediate medical attention if symptoms like swelling, hives, difficulty breathing occur.
Injection devices may contain dry natural rubber latex which can cause allergic reactions in sensitive individuals; ensure use of latex-free devices if allergic.
Discontinuation of therapy may cause LDL cholesterol levels to return to or exceed baseline; do not stop treatment without physician guidance.
Safety and efficacy in patients younger than 10 years have not been established; use outside approved age range is not recommended.
No evidence of significant drug-drug interactions but caution warranted when combining with concomitant lipid-lowering agents.
Pushtronex system requires adherence to detailed administration instructions to avoid improper dosing.
Avoid treatment interruption to prevent rebound in LDL-C levels and potential cardiovascular risk.
Monitor blood glucose as evolocumab may cause hyperglycemia in susceptible patients.
Advise patients to seek medical help immediately for signs of serious adverse reactions.
Risk of injection site infections if aseptic techniques are not followed.
Limited safety data in pregnant or breastfeeding women; weigh risks and benefits carefully.
Patients with hepatic impairment should be closely monitored despite minimal hepatic metabolism.
Report any unusual side effects or hypersensitivity reactions promptly to healthcare providers.
In patients receiving lipid apheresis, timing of dosing post-procedure is critical to therapeutic effectiveness.
Do not use expired product or product stored improperly as reduced efficacy and increased adverse effects may occur.

Contraindication

Known hypersensitivity to evolocumab or any component of the injection formulation.
Allergy or severe sensitivity to any ingredients in the Repatha injection device including dry natural rubber latex in certain presentations unless latex-free option is used.
Not approved for pediatric patients younger than 10 years of age.
Contraindicated in patients with a history of severe anaphylactic reaction to monoclonal antibodies.
Should not be administered intravenously or via any route other than subcutaneous injection.
Not a substitute for emergency treatment of acute cardiovascular events; contraindicated when prompt lipid-lowering is insufficient alone.
Contraindicated in patients with active infections at injection sites until resolved.
Use caution in patients with pre-existing immunologic disorders; avoid if risk outweighs benefit.
Incompatible with co-administration of investigational PCSK9 inhibitors or lipid-lowering agents without prior evidence of safety.
Contraindicated if improper storage or contamination of the drug product is suspected.
Not indicated for use in patients with normocholesterolemia or without established indications.
Contraindicated in patients who cannot tolerate subcutaneous injections or lack adequate caregiver support.
Do not use concurrently with other evolocumab biosimilars or replicates without medical oversight.
Avoid use in settings lacking appropriate medical supervision in case of adverse reactions.
Contraindicated where the patient refuses or is non-adherent to injection therapy and monitoring.

Drug Interactions

Minimal drug-drug interactions due to non-CYP450 metabolism; low potential for pharmacokinetic interactions.
No significant interactions identified with statins, ezetimibe, or other lipid-lowering agents used concomitantly.
Repatha may be co-administered safely with antihypertensives and antiplatelet agents without dose adjustments.
No clinically relevant effects observed when combined with immunosuppressants or chemotherapeutic agents.
No interaction with common agents affecting hepatic enzymes or renal transporters.
Concomitant use with other PCSK9 inhibitors is not recommended due to lack of safety data.
No interference with oral contraceptives or hormone replacement therapies.
Safe use demonstrated with anticoagulants and antidiabetic agents, but monitor blood glucose when indicated.
No reported interactions with herbal supplements or vitamins; however, patients should disclose all use.
No interference with vaccines documented; standard vaccination schedules maintained.
Potential immunogenicity does not appear to alter the efficacy or safety of other therapies.
Interactions with other biologics have not been fully studied; caution advised.
No known effect on drugs that modulate cytochrome P450 or UDP-glucuronosyltransferase pathways.
No evidence of altered pharmacodynamics with antiretroviral or antiviral medications.
Monitoring recommended when initiating or stopping other lipid-modifying therapies to assess additive or synergistic effects.

Preparations Of The Drug

Injection solution: 140 mg/mL prefilled single-dose SureClick autoinjector (with or without natural rubber latex in needle cover).
Injection solution: 140 mg/mL prefilled single-dose syringe (available with or without latex components).
Injection solution: 420 mg/3.5 mL single-dose Pushtronex on-body infusor system with prefilled cartridge (latex-free).
Contains active ingredient evolocumab, a human monoclonal antibody.
Inactive ingredients include proline, acetate, polysorbate 80, water for injection USP, and sodium hydroxide for pH adjustment.
Available in original packaging requiring refrigeration (2°C to 8°C) and protection from light.
Single-use devices are disposable and should be discarded in appropriate sharps containers after administration.
Latex sensitivity considerations require prescribing of latex-free formulation variants when needed.
Prefilled devices designed for ease of subcutaneous administration with safety features to reduce needle-stick injuries.
Specific instructions for storage, handling, and injection technique provided with each preparation.
Shelf life is typically up to expiration date when stored refrigerated; room temperature use permitted up to 30 days.
Not to be frozen or exposed to high temperatures; infected or compromised devices must not be used.
Prefilled syringes and autoinjectors are supplied sterile and contain no preservatives.
Packaging includes detailed instructions and patient information leaflets to optimize adherence and safety.
Pushtronex system enables slow infusion over approximately 9 minutes for 420 mg dose with hands-free delivery.